<DOC>
	<DOCNO>NCT01620060</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter , single multiple ascend lurasidone dose study subject 6 17 year old schizophrenia spectrum , bipolar spectrum , autistic spectrum disorder , psychiatric disorder .</brief_summary>
	<brief_title>Lurasidone Pediatric Pharmacokinetics Study</brief_title>
	<detailed_description>To characterize lurasidone PK profile follow single multiple oral dos 20 , 40,80 , 120 160 mg/day lurasidone target pediatric/adolescent population ( 6-17 year old ) schizophrenia spectrum , bipolar spectrum , autistic spectrum disorder psychiatric disorder . Data study use recommend pediatric dos result comparable exposure observe currently approve adult dos Latuda® ( 40 , 80 , 120 160 mg/day ) subsequent efficacy safety study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subjects must provide write informed consent , emancipate , write assent willing participate study . Written inform consent parent ( ) legal guardian ( ) sufficient intellectual capacity understand study support subject ' adherence study procedure must obtain subject emancipate . Male female subject 6 17 year age , inclusive . Subject must 17 year less followup visit . Subject judge investigator clinically stable ( ie , psychiatric hospitalization within past 12 week ; imminent risk suicide injury self , others property ; recent addition , change dosage , psychotropic medication intend treatment primary psychiatric condition past 4 week ) symptomatic ( ie , active symptom primary psychiatric condition present atypical antipsychotic agent judge acceptable treatment option ) . Subjects follow diagnosis eligible participation : primary schizophrenia spectrum diagnosis ( schizophrenia , schizoaffective , schizophreniform psychotic disorder Not Otherwise Specified ( NOS ) , bipolar spectrum disorder ( bipolar I , II bipolar NOS ) , pervasive developmental disorder ( PDD ) include autistic spectrum disorder ( autistic disorder , Asperger 's syndrome , Pervasive Developmental DisorderNot Otherwise Specified ( PDDNOS ) , attentiondeficit hyperactivity ( ADHD ) aggressive behavior [ meeting comorbid diagnostic criterion Conduct Disorder/Disruptive Behavior Disorders Not Otherwise Specified ( CD/DBD NOS ) , Tourette 's syndrome , via clinical interview ( use MINIKid plus diagnostic interview Diagnostic Statistical Manual Mental Disorders , 4th edition Text Revision ( DSMIVTR ) reference ) . Autistic disorder also confirm Autism Diagnostic Interview , Revised ( ADIR ) . Within 5th 95th percentile gender specific weightforage heightforage Growth Charts National Center Health Statistics . No clinically relevant abnormal laboratory value . No clinically relevant abnormal vital sign values/findings . Females participate study : unable become pregnant ( eg , premenarchal , surgically sterile etc ) OR willing remain sexually abstinent ( engage sexual intercourse ) Day 1 30 day discharge Day 11 ; OR sexually active willing use effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) Day 1 30 day discharge Day 11 . Males must willing remain sexually abstinent use effective method birth control ( eg , condom ) Day 1 30 day discharge Day 11 . Willing able remain antipsychotic medication lurasidone duration study , , investigator 's opinion subject risk worsening symptom . Willing able swallow size number lurasidone tablet specify per protocol . Willing able adhere protocolspecified meal requirement dose . Have stable living arrangement least 3 month prior Day 1 agree return similar living arrangement discharge Day 11 . Homeless subject may enrol . Clinically significant neurological , metabolic ( include type 1 diabetes ) , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , carcinoma , and/or urological disorder unstable angina , congestive heart failure ( uncontrolled ) , central nervous system ( CNS ) infection would pose risk subject participate study might confound result study . Note : Active medical condition minor wellcontrolled exclusionary affect risk subject study result . In case impact condition upon risk subject study result unclear , Medical Monitor consult . Any subject know cardiovascular disease condition ( even control ) must discuss Medical Monitor enrol study . Evidence chronic organic disease CNS tumor , inflammation , active seizure disorder , vascular disorder , Parkinson 's disease , form dementia , myasthenia gravis , degenerative process . In addition , subject must history mental retardation persistent neurological symptom attributable serious head injury . Past history febrile seizure , druginduced seizure , alcohol withdrawal seizure exclusionary . Known presence history hepatic insufficiency subject 's estimate creatinine clearance &lt; 80 mL/min/1.73 m2 follow Bedside Schwartz equation use creatinine method calibration traceable isotope dilution mass spectrometry ( IDMS ) : Creatinine clearance ( mL/min/1.73 m2 ) = ( 0.41 height ) / serum creatinine concentration , height cm serum creatinine mg/dL . Clinically significant finding ( ) physical examination determine investigator pose health concern subject study . A history presence abnormal ECG , investigator 's opinion clinically significant . Screening ECGs centrally overread , eligibility determine base overread . Known history presence clinically significant intolerance antipsychotic medication include limited angioedema , serotonin neuroleptic malignant syndrome , moderate severe dystonia , moderate severe tardive dyskinesia . Clinically significant alcohol abuse/dependence drug abuse/dependence base MINIKid criterion within last 6 month prior screen . Clinically significant orthostatic hypotension ( ie , drop systolic blood pressure 20 mmHg and/or drop diastolic blood pressure 10 mmHg within 3 minute stand ) . Presence history ( within last year ) medical surgical condition ( eg , gastrointestinal disease ) might interfere absorption , metabolism , excretion orally administer lurasidone . Positive breath alcohol test screen Day 1 . Positive test result screen Day 1 : Urine drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine , cannabinoids , methadone ) . However , positive test amphetamine , barbiturate , opiate , benzodiazepine methadone may result exclusion subject investigator determines positive test result prescription medicine ( ) . Pregnancy test ( female subject ≥ 8 year old ) . Lifetime history human immunodeficiency virus ( HIV ) positive acquire immune deficiency syndrome ( AIDS ) , history Hepatitis B C , positive test Hepatitis B C screening ( subject without history ) . Participated another clinical trial receive investigational product within 30 day prior study drug administration . Use inhibitor inducer CYP3A4 take within 28 day prior drug administration discharge Day 11 . Exceptions ( eg , grapefruit juice consumption ) may discuss casebycase basis medical monitor . Use concomitant medication consistently prolong QT/QTc interval within 28 day prior Day 1 followup . Received depot neuroleptic unless last injection least 1 month 1 treatment cycle prior Screening , whichever longer . Received treatment antidepressant within 3 day , fluoxetine olanzapine plus fluoxetine combination within 28 day , MAO inhibitor within 14 day prior Day 1 followup . Use antipsychotic medication ( study drug ) , carbamazepine , oxcarbazepine fluvoxamine , within 3 day prior Day 1 ( 7 day prior Day 1 aripiprazole ) followup . Does tolerate venipuncture bleed disorder would complicate blood draw . Females pregnant , lactating , likely become pregnant study . Donation loss whole blood within 60 day prior drug administration . Has prolactin concentration great equal 100 ng/mL screening . Unwilling abstain vigorous exercise Days 1 1 Days 9 10 . Subject answer `` yes '' `` Suicidal Ideation '' Items 4 5 CSSRS . Subject consider investigator imminent risk suicide injury self , others , property study . Subject history one serious suicide attempt ( base investigator 's judgment ) 12 month prior screen . Subjects determine risk suicide injury , assess investigator screening , refer psychiatric evaluation . Clinically relevant history drug hypersensitivity lurasidone component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>autism</keyword>
	<keyword>bipolar</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>